Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PIERRE FABRE MEDICAMENT

Home Clinical Trial Sponsors and OrganizationsPIERRE FABRE MEDICAMENT

PIERRE FABRE MEDICAMENT

P2, 3RD FLOOR, RAGHUVANSHI MILLS COMPOUND 11/12, Mumbai, Maharashtra, India

Also known as:

pierre fabre dermatologie

suc pierre fabre medicament

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

327

254 active

Approvals

43

Total approvals

Agencies

4

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

148

45.3%

Phase 2

18

5.5%

Phase 3

18

5.5%

Not Applicable

6

1.8%

Phase 4

4

1.2%

Trial Status Distribution

Active, not recruiting

253

77.4%

Completed

56

17.1%

Not yet recruiting

1

0.3%

Recruiting

7

2.1%

Terminated

5

1.5%

Unknown

1

0.3%

Withdrawn

4

1.2%

Clinical Trials

Trials sponsored by this organization (327)

An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients With Early Breast Cancer Treated With Adjuvant Endocrine Therapy - BCARE (Breast Cancer Adjuvant Real-world Evaluation of Dermatological Adverse Events)

Nov 2024155 participants

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

Oct 2024140 participants

Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

Sep 2024171 participants

To Describe How Well Vinorelbine Given Orally Works in Patients With a Breast Cancer After 2 Years of Treatment

Active, not recruiting

Sep 2024368 participants

An open-label Phase 2 trial to investigate efficacy and safety of intraamniotic administrations of ER004 to male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED)

Mar 202413 participants

The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study

Mar 202412 participants

Effects of Nicotine 1.5mg lozenge on smoking urges in moderate smokers

Active, not recruiting

Nov 2023180 participants

First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations

Sep 2023345 participants

Page 1 of 41

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

7

Approvals

EMA

European Medicines Agency

12

Approvals

SFDA

Saudi Food and Drug Authority

8

Approvals

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

16

Approvals

Recent Approvals

ALOPEXY 5% topical solution

NAVELBINE 10MG-ML I-V VIAL

NAVELBINE 10MG-ML I-V VIAL

CURACNE 10MG SOFT GELATIN CAPSULE

CURACNE 40MG SOFT GELATIN CAPSULE

ALOPEXY 5% topical solution

CURACNE 20MG SOFT GELATIN CAPSULE

Encorafenib Capsules

MEKTOVI 15 MG COMPRIMIDOS RECUBIERTOS CON PELICULA

News

No news articles found

On this page

Overview
Clinical Trials327
Approvals43
News

Back to Organizations